7-Chloro-5-[(3-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1,5-benzothiazepin-4-one

Catalog No. :
ACEQNJ519
CAS No. :
341967-92-8
Molecular Formula :
C16H13ClFNOS
Molecular Weight :
321.80

IUPAC Name:7-chloro-5-(3-fluorobenzyl)-2,3-dihydrobenzo[b][1,4]thiazepin-4(5H)-one

7-Chloro-5-[(3-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1,5-benzothiazepin-4-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g90%$323.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name7-Chloro-5-[(3-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1,5-benzothiazepin-4-one
IUPAC Name7-chloro-5-(3-fluorobenzyl)-2,3-dihydrobenzo[b][1,4]thiazepin-4(5H)-one
MDL No.MFCD01569040
Molecular FormulaC16H13ClFNOS
Molecular Weight321.80
SMILESO=C1CCSC2=CC=C(Cl)C=C2N1CC3=CC=CC(F)=C3
InChI KeyFMIZSGFQDMUAFU-UHFFFAOYSA-N
Synonym7-CHLORO-5-(3-FLUOROBENZYL)-2,3-DIHYDRO-1,5-BENZOTHIAZEPIN-4(5H)-ONE;7-chloro-5-[(3-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1,5-benzothiazepin-4-one;1,5-Benzothiazepin-4(5H)-one, 7-chloro-5-[(3-fluorophenyl)methyl]-2,3-dihydro-
CAS No.341967-92-8

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACEQNJ519 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACEQNJ519 route product structure diagram
    ACEQNJ519341967-92-8
Inquiry

2. ACEQNJ519 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACEQNJ519 route product structure diagram
    ACEQNJ519341967-92-8
Inquiry

Comments (0)